Literature DB >> 16019168

Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes.

Cara L Frankenfeld1, Anne McTiernan, Wendy K Thomas, Kristin LaCroix, Lynda McVarish, Victoria L Holt, Stephen M Schwartz, Johanna W Lampe.   

Abstract

OBJECTIVES: Intestinal bacterial metabolize the soy isoflavone daidzein to O-desmethylangolensin (O-DMA) or equol. Some individuals do not excrete O-DMA or equol after soy consumption, suggesting they do not harbor bacteria capable of producing these metabolites. The aim of this study was to evaluate bone mineral density (BMD) in relation to presence of these urinary metabolites.
METHODS: BMD, determined by whole-body dual X-ray absorptiometry scan, was age-adjusted and evaluated in relation to O-DMA-producer and equol-producer phenotypes in 92 postmenopausal women, aged 50-75 years. Women consumed supplemental soy foods (daidzein source) for 3 days and collected a first-void urine sample on the fourth day in order to determine metabolic phenotypes.
RESULTS: In O-DMA producers (n=76) compared to O-DMA non-producers (n=16), greater total, leg and head BMD (p<0.05) were observed. Total BMD among the O-DMA producers (geometric mean=1.04 g/cm2) was 6% greater than total BMD among the O-DMA non-producers (geometric mean=0.98 g/cm2). Total and site-specific BMD did not differ between equol producers (n=24) and non-producers (n=68) (p>0.05). In exploratory analyses, among regular soy consumers, spinal BMD was 20% lower among the equol producers than non-producers, whereas, among soy non-consumers, no such difference was observed (p-interaction<0.05). Among equol producers, circulating estrone and free estradiol concentrations were inversely or not associated with total BMD, whereas, among equol non-producers, these hormones were positively associated (p-interaction<0.05).
CONCLUSIONS: Our results provide evidence that intestinal bacterial composition may influence BMD in postmenopausal women. Further studies characterizing associations of intestinal bacterial profiles with BMD are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019168     DOI: 10.1016/j.maturitas.2005.05.016

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  12 in total

1.  Impact of food matrix on isoflavone metabolism and cardiovascular biomarkers in adults with hypercholesterolemia.

Authors:  Jennifer Ahn-Jarvis; Steven K Clinton; Kenneth M Riedl; Yael Vodovotz; Steven J Schwartz
Journal:  Food Funct       Date:  2012-06-27       Impact factor: 5.396

2.  Equol, via dietary sources or intestinal production, may ameliorate estrogen deficiency-induced bone loss.

Authors:  Connie M Weaver; Leecole L Legette
Journal:  J Nutr       Date:  2010-05-26       Impact factor: 4.798

Review 3.  Does equol production determine soy endocrine effects?

Authors:  Dana Shor; Thozhukat Sathyapalan; Stephen L Atkin; Natalie J Thatcher
Journal:  Eur J Nutr       Date:  2012-02-25       Impact factor: 5.614

4.  Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States.

Authors:  Charlotte Atkinson; Katherine M Newton; Mellissa Yong; Frank Z Stanczyk; Kim C Westerlind; Lin Li; Johanna W Lampe
Journal:  Metabolism       Date:  2012-07-21       Impact factor: 8.694

5.  Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein.

Authors:  C L Frankenfeld; C Atkinson; K Wähälä; J W Lampe
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 6.  Phytoestrogenic isoflavonoids in epidemiologic and clinical research.

Authors:  Adrian A Franke; Brunhild M Halm; Kerry Kakazu; Xingnan Li; Laurie J Custer
Journal:  Drug Test Anal       Date:  2009-01       Impact factor: 3.345

7.  Supplemental dietary racemic equol has modest benefits to bone but has mild uterotropic activity in ovariectomized rats.

Authors:  Leecole L Legette; Berdine R Martin; Mohammad Shahnazari; Wang-Hee Lee; William G Helferich; Junqi Qian; David J Waters; Alireza Arabshahi; Stephen Barnes; Jo Welch; David G Bostwick; Connie M Weaver
Journal:  J Nutr       Date:  2009-08-26       Impact factor: 4.798

8.  Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures.

Authors:  Takuya Ohtomo; Mariko Uehara; José Luis Peñalvo; Herman Adlercreutz; Shin-ichi Katsumata; Kazuharu Suzuki; Ken Takeda; Ritsuko Masuyama; Yoshiko Ishimi
Journal:  Eur J Nutr       Date:  2008-07-11       Impact factor: 5.614

Review 9.  O-desmethylangolensin: the importance of equol's lesser known cousin to human health.

Authors:  Cara L Frankenfeld
Journal:  Adv Nutr       Date:  2011-06-28       Impact factor: 8.701

10.  Isoflavone metabolism and bone-sparing effects of daidzein-metabolites.

Authors:  Mariko Uehara
Journal:  J Clin Biochem Nutr       Date:  2013-05-01       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.